0000899243-20-010882.txt : 20200417 0000899243-20-010882.hdr.sgml : 20200417 20200417080021 ACCESSION NUMBER: 0000899243-20-010882 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200415 FILED AS OF DATE: 20200417 DATE AS OF CHANGE: 20200417 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Knobil Katharine CENTRAL INDEX KEY: 0001768011 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38822 FILM NUMBER: 20797756 MAIL ADDRESS: STREET 1: C/O KALEIDO BIOSCIENCES, INC. STREET 2: 65 HAYDEN AVE. CITY: LEXINGTON STATE: MA ZIP: 02421 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Kaleido Biosciences, Inc. CENTRAL INDEX KEY: 0001751299 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 18 CROSBY DRIVE CITY: BEDFORD STATE: MA ZIP: 01730 BUSINESS PHONE: 617-674-9000 MAIL ADDRESS: STREET 1: 18 CROSBY DRIVE CITY: BEDFORD STATE: MA ZIP: 01730 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-04-15 0 0001751299 Kaleido Biosciences, Inc. KLDO 0001768011 Knobil Katharine C/O KALEIDO BIOSCIENCES, INC. 65 HAYDEN AVE. LEXINGTON MA 02421 0 1 0 0 See Remarks Stock Option (Right to Buy) 6.00 2020-04-15 4 A 0 67500 0.00 A 2030-04-14 Common Stock 67500 67500 D 25% of this option shall vest on April 15, 2021, with the remaining 75% vesting in 12 equal quarterly installments thereafter. Chief Medical Officer and Head of Research and Development /s/ Alison Lawton, as Attorney-in-Fact 2020-04-17